Compound 068

Compound 068 is a synthetic chalcone-based small molecule inhibitor developed for the treatment of ovarian cancer. Identified through computational 3D-QSAR (Quantitative Structure-Activity Relationship) modeling and subsequently validated in experimental assays, the compound demonstrates potent antiproliferative activity against the A2780 ovarian cancer cell line. Its mechanism of action involves the induction of intracellular reactive oxygen species (ROS), which triggers apoptotic pathways in malignant cells. Compound 068 is specifically designed to address the challenges of late-stage diagnosis and chemoresistance in gynecological malignancies, representing a promising scaffold for the development of targeted antineoplastic therapies.